This Plain Language Summary of Publication article (PLSP) from Future Endocrinology & Metabolism includes information from two identical studies (SKYLIGHT 1 and 2) conducted in Europe and North America between 2019-2021 tested fezolinetant’s effectiveness in treating menopausal hot flashes and night sweats. Participants received either fezolinetant or a matching placebo pill. The research evaluated the frequency and severity of hot flashes, along with monitoring side effects, sleep issues, and overall quality of life impact.

Visit the site using this link to read the article.

This PLSP is based on two articles called ‘Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT’ published in The Journal of Clinical Endocrinology & Metabolism and ‘Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study’ and was published in The Lancet.

Visit Oxford Academic using the link to read the original article.

Visit The Lancet using the link to read the original article.